VBIT-12
目录号 : GC39458
VBIT-12是一种独特的VDAC1抑制蛋白。
Cas No.:2089227-65-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
VBIT-12 is a unique inhibitory protein for VDAC1 [1]. VBIT-12 induces VDAC1 binding, inhibits and promotes decay protein interaction, and inhibits granular membrane voltage potential and decreases cellular pigment C release, leading to anti-decay action [2]. VBIT-12 is commonly used to treat inflammation and cardiovascular diseases [3-4].
In colon cells, VBIT-12 (10µM, 20µM; 48h) treatment of cultured colon cells inhibit DSS-induced VDAC1 overexpression, oligomerization, and apoptosis [5]. In murine hepatocytes, VBIT-12 (20µM; 2h) protects mitochondria and alleviates APAP-induced ferroptosis [6]. In R28 retinal neuron-like cells, VBIT-12 (40µM; 2h) inhibits OGD/R-induced mitochondrial damage and attenuates cell death [7].
In SOD1G93A transgenic mice, receiving intraperitoneal injection of VBIT-12 (13mg/kg, 26mg/kg; ip; 12 weeks) maintained limb muscle strength for a longer period of time [8]. In 5×FAD transgenic mice, VBIT-12 (20mg/kg; po; 5 months) inhibits cognitive decline in mice [9]. In the caerulein hyperstimulation-induced pancreatitis mice model (CER), prophylactic administration of VBIT-12 (20mg/kg; po; 24h) attenuated pancreatic histological damage, significantly reduced VDAC1 oligomerization, and decreased serum amylase levels and pancreatic trypsin activity [10].
References:
[1]. Shoshan-Barmatz V, Nahon-Crystal E, Shteinfer-Kuzmine A, et al. VDAC1, mitochondrial dysfunction, and Alzheimer's disease. Pharmacological research. 2018 May 1; 131: 87-101.
[2]. Magri A, Cubisino SA, Battiato G, et al. VDAC1 knockout affects mitochondrial oxygen consumption triggering a rearrangement of ETC by impacting on complex I activity. International Journal of Molecular Sciences. 2023 Feb 12; 24(4): 3687.
[3]. Shoshan-Barmatz V, Anand U, Nahon-Crystal E, et al. Adverse effects of metformin from diabetes to COVID-19, cancer, neurodegenerative diseases, and aging: is VDAC1 a common target?. Frontiers in physiology. 2021 Oct 4; 12: 730048.
[4]. Song JQ, Shen LJ, Wang HJ, et al. Discovery of Balasubramide Derivative with Tissue‐Specific Anti‐Inflammatory Activity Against Acute Lung Injury by Targeting VDAC1. Advanced Science. 2024 Dec;11(48): 2410550.
[5]. Verma A, Pittala S, Alhozeel B, et al. The role of the mitochondrial protein VDAC1 in inflammatory bowel disease: a potential therapeutic target. Molecular Therapy. 2022 Feb 2; 30(2): 726-744.
[6]. Niu B, Lei X, Xu Q, et al. Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury. Cell biology and toxicology. 2022 Jun 1: 1-26.
[7]. Wan H, Yan YD, Hu XM, et al. Inhibition of mitochondrial VDAC1 oligomerization alleviates apoptosis and necroptosis of retinal neurons following OGD/R injury. Annals of Anatomy-Anatomischer Anzeiger. 2023 Apr 1; 247: 152049.
[8]. Shteinfer-Kuzmine A, Argueti-Ostrovsky S, Leyton-Jaimes MF, et al. Targeting the mitochondrial protein VDAC1 as a potential therapeutic strategy in ALS. International Journal of Molecular Sciences. 2022 Sep 1; 23(17): 9946.
[9]. Verma A, Shteinfer-Kuzmine A, Kamenetsky N, et al. Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology. Translational Neurodegeneration. 2022 Dec 28; 11(1): 58.
[10]. Chanda D, Thoudam T, Sinam IS, et al. Upregulation of the ERRγ–VDAC1 axis underlies the molecular pathogenesis of pancreatitis. Proceedings of the National Academy of Sciences. 2023 May 16; 120(20): e2219644120.
VBIT-12是一种独特的VDAC1抑制蛋白 [1]。VBIT-12诱导VDAC1结合，抑制并促进衰变蛋白相互作用，抑制颗粒膜电位并减少细胞色素C释放，从而发挥抗衰变作用 [2]。VBIT-12常用于治疗炎症和心血管疾病 [3-4]。
在结肠细胞中，VBIT-12（10µM、20µM；48h）处理培养的结肠细胞可抑制DSS诱导的VDAC1过表达、寡聚化和细胞凋亡 [5]。在小鼠肝细胞中，VBIT-12（20µM；2h）可保护线粒体并减轻APAP诱导的铁死亡 [6]。在R28视网膜类神经元细胞中，VBIT-12（40µM；2h）可抑制OGD/R诱导的线粒体损伤并减轻细胞死亡 [7]。
在SOD1G93A转基因小鼠中，腹膜内注射VBIT-12（13mg/kg，26mg/kg；ip；12周）可维持较长时间的肢体肌肉强度 [8]。在5×FAD转基因小鼠中，VBIT-12（20mg/kg；po；5个月）可抑制小鼠的认知能力下降 [9]。在青霉素过度刺激诱发的胰腺炎小鼠模型（CER）中，预防性给予VBIT-12（20mg/kg；po；24h）可减轻胰腺组织学损伤，显著降低VDAC1寡聚化，并降低血清淀粉酶水平和胰腺胰蛋白酶活性 [10]。
| Cell experiment [1]: | |
Cell lines | Colon cells |
Preparation Method | Cells (60% confluence) were incubated for 48h in a serum-free growth medium with different concentrations of DSS (dissolved in culture media and filter-sterilized using a 0.45μm filter) in triplicates. Cells were treated with different concentrations of DSS (1%–3%) in the absence or presence of VBIT-12 and analyzed for cell viability, VDAC1 expression levels, VDAC1 oligomerization, ROS production, mtDNA release, and apoptosis. |
Reaction Conditions | 10µM, 20µM; 48h |
Applications | VBIT-12 treatment of cultured colon cells inhibits DSS-induced VDAC1 overexpression, oligomerization, and apoptosis. |
| Animal experiment [2]: | |
Animal models | SOD1G93A transgenic mice |
Preparation Method | For intraperitoneal (IP) injection, VBIT-12 (80mg/mL) in DMSO was diluted with saline, pH 7.0, to a final concentration of 3.25mg/mL. SOD1G93A transgenic mice received 200µL by IP injection resulting in a final VBIT-12 concentration of ~26mg/kg. VBIT-12 was IP injected every second day starting from day 60 for 12 weeks, and then the VBIT-12 final concentration was reduced to ~13mg/kg. The control group was IP injected with around 200µL of DMSO (4%). |
Dosage form | 13mg/kg, 26mg/kg; ip; 12 weeks |
Applications | SOD1G93A transgenic mice receiving intraperitoneal injection of VBIT-12 maintained limb muscle strength for a longer period of time. |
References: | |
| Cas No. | 2089227-65-4 | SDF | |
| Canonical SMILES | O=C(O)CNC(C1(NC2=CC=CC=C2)CCN(CC3=C4C=CC=CC4=CC=C3)CC1)=O | ||
| 分子式 | C25H27N3O3 | 分子量 | 417.5 |
| 溶解度 | DMSO: 250 mg/mL (598.80 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3952 mL | 11.976 mL | 23.9521 mL |
| 5 mM | 0.479 mL | 2.3952 mL | 4.7904 mL |
| 10 mM | 0.2395 mL | 1.1976 mL | 2.3952 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet